Program Information

MRI-Based Motion Management for RT

E Tryggestad

X Zhong

C Glide-Hurst

E Tryggestad¹*, X Zhong²*, C Glide-Hurst³*, (1) Mayo Clinic, Rochester, MN, (2) Siemens (3) Henry Ford Health System, Farmington Hills, MI

Presentations

TU-F-BRB-0 (Tuesday, July 14, 2015) 2:45 PM - 3:45 PM Room: Ballroom B

The current clinical standard of organ respiratory imaging, 4D-CT, is fundamentally limited by poor soft-tissue contrast and imaging dose. These limitations are potential barriers to beneficial “4D” radiotherapy methods which optimize the target and OAR dose-volume considering breathing motion but rely on a robust motion characterization. Conversely, MRI imparts no known radiation risk and has excellent soft-tissue contrast. MRI-based motion management is therefore highly desirable and holds great promise to improve radiotherapy of moving cancers, particularly in the abdomen. Over the past decade, MRI techniques have improved significantly, making MR-based motion management clinically feasible. For example, cine MRI has high temporal resolution up to 10 f/s and has been used to track and/or characterize tumor motion, study correlation between external and internal motions. New MR technologies, such as 4D-MRI and MRI hybrid treatment machines (i.e. MR-linac or MR-Co60), have been recently developed. These technologies can lead to more accurate target volume determination and more precise radiation dose delivery via direct tumor gating or tracking. Despite all these promises, great challenges exist and the achievable clinical benefit of MRI-based tumor motion management has yet to be fully explored, much less realized. In this proposal, we will review novel MR-based motion management methods and technologies, the state-of-the-art concerning MRI development and clinical application and the barriers to more widespread adoption.

Learning Objectives:
1. Discuss the need of MR-based motion management for improving patient care in radiotherapy.
2. Understand MR techniques for motion imaging and tumor motion characterization.
3. Understand the current state of the art and future steps for clinical integration.


Funding Support, Disclosures, and Conflict of Interest: Henry Ford Health System holds research agreements with Philips Healthcare. Research sponsored in part by a Henry Ford Health System Internal Mentored Grant.


Contact Email: